Tourmaline US-MM6, an Open-Label, Single-Arm, Multicenter Study Evaluating the Effectiveness and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) in Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Switching from a Bortezomib-Based Triplet Induction Regimen
Robert M. Rifkin(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Stephen J. Noga, Suman Kambhampati(Veterans Health Administration), Joshua Richter(Tisch Hospital), Lawrence E Dollar(Takeda (United States)), Liviu Niculescu(Takeda (United States)), Magdalena Schoeneich(Takeda (United States)), Brittany Sickler(Takeda (United States)), Susan Zelt(Takeda (United States)), Bingxia Wang(Takeda (United States)), Ralph V. Boccia(Center for Cancer and Blood Disorders), Jack Aiello(Empowerment Program), Presley Whidden(Millennium Engineering and Integration (United States)), Saad Z. Usmani(Memorial Sloan Kettering Cancer Center)
Cited by 5
Related Papers
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
|Journal of Clinical Oncology|2022|647
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
|The Lancet Oncology|2019|493